Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7089
Source ID: NCT01101945
Associated Drug: Dutogliptin
Title: Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: dutogliptin
Outcome Measures: Primary: To demonstrate safety and tolerability of dutogliptin/PHX1149T as assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments, 104 weeks|To demonstrate safety and tolerability of dutogliptin/PHX1149Tas assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments, 208 weeks (U.S. only) | Secondary: To demonstrate maintenance or lowering of HbA1c and fasting blood glucose, 104 weeks
Sponsor/Collaborators: Sponsor: Phenomix
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 339
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2007-07
Completion Date: 2010-03
Results First Posted:
Last Update Posted: 2010-08-11
Locations: Fullerton, California, United States|Long Beach, California, United States|Orange, California, United States|San Diego, California, United States|Kissimmee, Florida, United States|Melbourne, Florida, United States|New Port Richey, Florida, United States|Gurnee, Illinois, United States|Wichita, Kansas, United States|Kansas City, Missouri, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Margate City, New Jersey, United States|Trenton, New Jersey, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Warminster, Pennsylvania, United States|Columbia, South Carolina, United States|Greer, South Carolina, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Cuidad Autonoma de Buenos Aires, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Lanus Este, Buenos Aires, Argentina|Moron, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Corrientes, Argentina|Calgary, Alberta, Canada|Red Deer, Alberta, Canada|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Samia, Ontario, Canada|Toronto, Ontario, Canada|Cornwall, Prince Edward Island, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Ellisbridge, Ahmedabad, India|Banjara Hills, Hyderabad, India|Punjagutta, Hyderabad, India|Pune, Maharashtra, India|Tardeo, Mumbai, India|Dhantoli, Nagpur, India|Chennai, Tamilnadu, India|Mexico City, Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Morelia, Michoacan, Mexico|Monterrey N. L., Nuevo Leon, Mexico
URL: https://clinicaltrials.gov/show/NCT01101945

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress